Outlook Therapeutics Files 8-K
Ticker: OTLK · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1649989
| Field | Detail |
|---|---|
| Company | Outlook Therapeutics, Inc. (OTLK) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
Related Tickers: OTLK
TL;DR
OTLK filed an 8-K on 8/28/25 for routine corporate updates.
AI Summary
Outlook Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting other events and financial statements. The company, formerly known as Oncobiologics, Inc., is incorporated in Delaware and headquartered in Iselin, New Jersey.
Why It Matters
This filing indicates routine corporate reporting, including financial statements and other events, which is standard for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for corporate events and financial statements, not indicating any immediate material changes or risks.
Key Numbers
- 001-37759 — Commission File Number (Identifier for the company's SEC filings)
- 38-3982704 — IRS Employer Identification No. (Tax identification number for the company)
Key Players & Entities
- Outlook Therapeutics, Inc. (company) — Registrant
- Oncobiologics, Inc. (company) — Former company name
- August 28, 2025 (date) — Date of earliest event reported
- 111 S. Wood Avenue, Unit #100 (address) — Principal executive offices
- Iselin, New Jersey 08830 (address) — Principal executive offices
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events' beyond listing it as an item information category.
When was Outlook Therapeutics, Inc. formerly known as Oncobiologics, Inc.?
The filing indicates the date of the name change was August 4, 2015.
What is the fiscal year end for Outlook Therapeutics, Inc.?
The fiscal year end for Outlook Therapeutics, Inc. is September 30.
What is the primary business of Outlook Therapeutics, Inc. according to its SIC code?
According to its SIC code [2836], the primary business is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
What is the filing date of this 8-K report?
The filing date, also the date as of change, is September 2, 2025, with the earliest event reported on August 28, 2025.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2025-09-02 17:00:49
Filing Documents
- tm2524956d1_8k.htm (8-K) — 25KB
- tm2524956d1_ex99-1.htm (EX-99.1) — 23KB
- tm2524956d1_ex99-1img001.jpg (GRAPHIC) — 6KB
- 0001104659-25-086428.txt ( ) — 225KB
- otlk-20250828.xsd (EX-101.SCH) — 3KB
- otlk-20250828_lab.xml (EX-101.LAB) — 33KB
- otlk-20250828_pre.xml (EX-101.PRE) — 22KB
- tm2524956d1_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated August 28, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Outlook Therapeutics, Inc. Date: September 2, 2025 By: /s/ Lawrence A. Kenyon Lawrence A. Kenyon Chief Financial Officer